Labcorp Holdings Inc. $LH Shares Acquired by Everett Harris & Co. CA

Everett Harris & Co. CA increased its stake in shares of Labcorp Holdings Inc. (NYSE:LH) by 3.9% in the 3rd quarter, Holdings Channel reports. The firm owned 129,602 shares of the medical research company’s stock after buying an additional 4,913 shares during the period. Labcorp accounts for approximately 0.5% of Everett Harris & Co. CA’s holdings, making the stock its 29th biggest position. Everett Harris & Co. CA’s holdings in Labcorp were worth $39,932,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the company. D.A. Davidson & CO. lifted its stake in shares of Labcorp by 3.0% in the 3rd quarter. D.A. Davidson & CO. now owns 21,540 shares of the medical research company’s stock worth $6,637,000 after purchasing an additional 619 shares during the period. William Mack & Associates Inc. bought a new position in Labcorp in the 3rd quarter worth $42,000. Generali Asset Management SPA SGR grew its position in shares of Labcorp by 3.1% during the third quarter. Generali Asset Management SPA SGR now owns 16,203 shares of the medical research company’s stock worth $4,992,000 after purchasing an additional 492 shares in the last quarter. Asset Management One Co. Ltd. grew its holdings in Labcorp by 2.1% during the 3rd quarter. Asset Management One Co. Ltd. now owns 37,153 shares of the medical research company’s stock valued at $11,447,000 after buying an additional 768 shares in the last quarter. Finally, Penobscot Investment Management Company Inc. raised its position in shares of Labcorp by 3.6% during the third quarter. Penobscot Investment Management Company Inc. now owns 8,718 shares of the medical research company’s stock valued at $2,686,000 after buying an additional 300 shares during the last quarter. Institutional investors own 95.94% of the company’s stock.

Insider Buying and Selling

In other Labcorp news, CEO Adam Schechter sold 4,669 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the transaction, the chief executive officer owned 102,565 shares in the company, valued at approximately $32,858,749.05. This represents a 4.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kerrii Anderson sold 3,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $318.02, for a total value of $954,060.00. Following the transaction, the director owned 6,563 shares in the company, valued at $2,087,165.26. This trade represents a 31.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 8,593 shares of company stock valued at $2,733,295. 0.84% of the stock is owned by company insiders.

Labcorp Stock Performance

Shares of LH stock opened at $367.49 on Friday. The firm has a market capitalization of $29.80 billion, a price-to-earnings ratio of 19.91, a price-to-earnings-growth ratio of 2.05 and a beta of 0.87. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.41 and a quick ratio of 1.53. The business has a fifty day moving average of $322.64 and a 200 day moving average of $287.05. Labcorp Holdings Inc. has a 1 year low of $244.52 and a 1 year high of $371.00.

Labcorp (NYSE:LH) last posted its quarterly earnings results on Wednesday, October 28th. The medical research company reported $4.78 earnings per share for the quarter, beating the consensus estimate of $4.64 by $0.14. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. The business had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the business earned $4.18 EPS. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. As a group, research analysts expect that Labcorp Holdings Inc. will post 18.36 earnings per share for the current year.

Labcorp Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Tuesday, November 24th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $2.88 dividend on an annualized basis and a yield of 0.8%. Labcorp’s payout ratio is presently 23.63%.

Key Stories Impacting Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Third-quarter results exceeded expectations. Adjusted EPS was $4.78 versus the $4.64 analyst consensus, while revenue rose 6.9% year over year to $3.81 billion, ahead of the $3.76 billion forecast. Both Diagnostics Laboratories and Biopharma Laboratory Services delivered growth, with revenue increasing 6.5% and 8.5%, respectively. Labcorp Q3 2026 earnings highlights
• Positive Sentiment: Labcorp raised its 2026 guidance. The company now expects enterprise revenue growth of 5.9% to 6.7% and adjusted EPS of $18.30 to $18.70, supported by margin expansion, organic growth and recent transactions. It also announced or completed four deals and received FDA approval for a companion diagnostic used in advanced melanoma. Labcorp boosts FY26 outlook
• Positive Sentiment: Analysts raised their targets. Truist increased its target to $395 and maintained a Buy rating, while Robert W. Baird raised its target to $396 and kept an Outperform rating. Truist raises Labcorp price target
• Neutral Sentiment: Deutsche Bank raised its price target to $355 but retained a Hold rating, indicating limited upside at elevated trading levels. Deutsche Bank adjusts Labcorp price target
• Negative Sentiment: PAMA reimbursement risk remains an overhang. Investors are concerned that potential changes to laboratory payment rules could pressure future reimbursement and earnings. One analyst also downgraded the stock, arguing that optimism and valuation may have become excessive. Labcorp stock and PAMA risk

Analysts Set New Price Targets

Several equities analysts have recently commented on LH shares. Weiss Ratings raised shares of Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a report on Wednesday, October 21st. Morgan Stanley restated an “overweight” rating and set a $388.00 price objective on shares of Labcorp in a research report on Thursday. Bank of America upped their target price on shares of Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Barclays boosted their target price on Labcorp from $330.00 to $380.00 and gave the company an “equal weight” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. increased their price objective on Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Labcorp currently has a consensus rating of “Moderate Buy” and a consensus target price of $365.67.

Labcorp Company Profile

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.